Drug Profile
AG B1622
Alternative Names: AG-B1622Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Ahn-Gook Pharmaceutical
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Cancer in South Korea
- 01 Jan 2018 Early research in Cancer in South Korea (unspecified route) (Ahn-Gook Pharmaceuticals pipeline, January 2018)